A Phase 1 Study of INCA033989 in People With Myeloproliferative Neoplasms

Full Title

Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Purpose

Researchers want to find the best dose of INCA033989 to use in people with myelofibrosis (MF) and essential thrombocytopenia (ET). These diseases are called myeloproliferative neoplasms. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change or variant) in the CALR exon-9 gene.

INCA033989 blocks a protein that can cause cancer cells to grow. By blocking this protein, INCA033989 may help slow or stop the growth of your cancer. INCA033989 is given intravenously (by vein).

Contact

For more information and to see if you can join this study, please call Dr. Raajit Rampal’s office at 646-608-3746.